Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
McKesson
Baxter
Moodys
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Otamixaban

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Otamixaban: Patents, clinical trial progress, indications

Otamixaban is an investigational drug.

There have been 5 clinical trials for Otamixaban. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2010.

The most common disease conditions in clinical trials are Acute Coronary Syndrome, Myocardial Infarction, and Infarction. The leading clinical trial sponsors are Sanofi and [disabled in preview].

There are thirty-six US patents protecting this investigational drug and six hundred and thirty-six international patents.

Recent Clinical Trials for Otamixaban
TitleSponsorPhase
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic ImpairmentSanofiPhase 1
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive StrategySanofiPhase 3
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal ImpairmentSanofiPhase 1

See all Otamixaban clinical trials

Clinical Trial Summary for Otamixaban

Top disease conditions for Otamixaban
Top clinical trial sponsors for Otamixaban

See all Otamixaban clinical trials

US Patents for Otamixaban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Otamixaban   Start Trial Crystalline forms of a factor Xa inhibitor Aventis Pharmaceuticals Inc. (Bridgewater, NJ)   Start Trial
Otamixaban   Start Trial Inhibitors of bruton's tyrosine kinase Pharmacyclics, Inc. (Sunnyvale, CA)   Start Trial
Otamixaban   Start Trial Inhibitors of tyrosine kinases and uses thereof Pharmacyclics, Inc. (Sunnyvale, CA)   Start Trial
Otamixaban   Start Trial Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase Pharmacyclics, Inc. (Sunnyvale, CA)   Start Trial
Otamixaban   Start Trial Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase Pharmacyclics, Inc. (Sunnyvale, CA)   Start Trial
Otamixaban   Start Trial Inhibitors of bruton's tyrosine kinase Pharmacyclics, Inc. (Sunnyvale, CA)   Start Trial
Otamixaban   Start Trial Skin-contacting-adhesive free dressing   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Otamixaban

Drugname Country Document Number Estimated Expiration Related US Patent
Otamixaban Austria 396177 2020-10-05   Start Trial
Otamixaban Australia 1142502 2020-10-05   Start Trial
Otamixaban Australia 2002211425 2020-10-05   Start Trial
Otamixaban Canada 2424565 2020-10-05   Start Trial
Otamixaban Cyprus 1108224 2020-10-05   Start Trial
Otamixaban Germany 60134162 2020-10-05   Start Trial
Otamixaban Denmark 1326838 2020-10-05   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Express Scripts
Merck
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.